Researchers at EPFL have unveiled BindCraft, an AI-powered pipeline capable of designing functional protein binders against diverse targets with remarkable 10–100% success rates without extensive experimental screening. Published in Nature and available under an MIT license, BindCraft rapidly generates high-affinity candidates in silico and is effective against therapeutically relevant receptors and CRISPR-associated nucleases. This innovation promises to accelerate therapeutic and diagnostic protein development, democratizing access to advanced protein engineering tools.